Evidence map›Paper›PMID 35290656›Full record

ReviewDrug delivery and translational research2022

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.

Hagar I Labouta, Robert Langer, Pieter R Cullis, Olivia M Merkel, Mark R Prausnitz, Yasmine Gomaa, Sara S Nogueira, Tushar Kumeria

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. A Patent Analysis on Nano Drug Delivery Systems.Recent patents on nanotechnology · 2025
    Review
  8. Review
  9. Safety of Zein Nanoparticles on Human Innate Immunity and Inflammation.International journal of molecular sciences · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Hagar I LaboutaCollege of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada. hagar.labouta@umanitoba.ca.ORCID 0000-0001-7344-5893
Robert Langer *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Pieter R Cullis *Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
Olivia M Merkel *Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University, 81337, Munich, Germany.
Mark R Prausnitz *School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Yasmine GomaaSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Sara S NogueiraSchool of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia.
Tushar KumeriaSchool of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.ORCID 0000-0003-3351-7148
Georgia Institute of Technology · USUNSW Sydney · AUChildren's Hospital Research Institute of Manitoba · CALudwig-Maximilians-Universität München · DEMassachusetts Institute of Technology · USUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The triumphant success of mRNA vaccines is a testimony to the important role drug delivery technologies have played in protecting billions of people against SARS-CoV-2 (or the Corona Virus Disease 2019; COVID-19). Several lipid nanoparticle (LNP) mRNA vaccines were developed and have been instrumental in preventing the disease by boosting the immune system against the pathogen, SARS-CoV-2. These vaccines have been built on decades of scientific research in drug delivery of mRNA, vaccines, and other biologicals. In this manuscript, several leading and emerging scientists in the field of drug delivery share their perspective on the role of drug delivery technologies in developing safe and efficacious vaccines, in a roundtable discussion. The authors also discussed their viewpoint on the current challenges, and the key research questions that should drive this important area of research.

Indexed as

COVID-19NanoparticlesViral VaccinesCOVID-19 VaccinesHumansLiposomesRNA, MessengerSARS-CoV-2COVID-19 VaccinesLipid NanoparticlesLiposomesRNA, MessengerViral VaccinesCOVID-19 vaccineDrug deliveryLipid nanoparticlesMicroneedlesPolymeric formulations

Identifiers

PMID35290656
PMCPMC8923087
OpenAlexW4221039611

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.